Non-Current Assets
Equity securities
Pfizer Equity securities decreased by 28.2% to $1.87B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 48.6%, from $1.26B to $1.87B. Over 5 years (FY 2020 to FY 2025), Equity securities shows an upward trend with a 35.6% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2017
Last reportedQ1 2026May 5, 2026
Metric ID:
ins_equity_securitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.28B | $2.37B | $5.37B | $2.76B | $4.37B | $12.15B | $1.59B | $1.17B | $17.64B | $13.19B | $5.12B | $2.48B | $975.00M | $1.42B | $7.85B | $1.26B | $1.69B | $2.39B | $2.60B | $1.87B |
| QoQ Change | — | +3.6% | +126.7% | -48.6% | +58.5% | +177.9% | -86.9% | -26.6% | >999% | -25.2% | -61.2% | -51.5% | -60.7% | +45.6% | +452.7% | -84.0% | +34.4% | +41.7% | +8.6% | -28.2% |
| YoY Change | — | — | — | — | +91.5% | +413.5% | -70.4% | -57.8% | +303.4% | +8.5% | +222.7% | +113.1% | -94.5% | -89.2% | +53.2% | -49.5% | +73.0% | +68.3% | -66.9% | +48.6% |
Range$975.00M – $17.64B
CAGR-4.2%
Avg YoY Growth+60.5%
Median YoY Growth+50.9%
Equity securities at Other Companies
Frequently Asked Questions
- What is Pfizer's equity securities?
- Pfizer (PFE) reported equity securities of $1.87B in Q1 2026.
- How has Pfizer's equity securities changed year-over-year?
- Pfizer's equity securities increased by 48.6% year-over-year, from $1.26B to $1.87B.
- What is the long-term trend for Pfizer's equity securities?
- Over 5 years (2020 to 2025), Pfizer's equity securities has grown at a 35.6% compound annual growth rate (CAGR), from $567.00M to $2.60B.